Lidocaine - NEMO consortium/Only for Children Pharmaceuticals

Drug Profile

Lidocaine - NEMO consortium/Only for Children Pharmaceuticals

Latest Information Update: 09 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NEMO Consortium; Only for Children Pharmaceuticals
  • Developer Only for Children Pharmaceuticals
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Neonatal seizures

Most Recent Events

  • 09 May 2016 Chemical structure information added
  • 31 Mar 2015 Preclinical trials in Neonatal seizures in France (unspecified route) before March 2015
  • 01 Feb 2015 NEMO Consortium submits Paediatric Investigation Plan to EMA for Neonatal seizures
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top